300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Energy
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Sports
Education
Automotive
Wellness
Biotechnology
eSports
Legal
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Recruiting
Infrastructure
Web3
Medical
Beauty
Fashion
Theatre
Climate
Life Science
LGBT
Food and Beverage
Cannabis
Publishing
Celebrity
Mobile Apps
Music
Wine and Spirits
Art
Real Estate
Sporting Goods
Manufacturing
Social Media
FinTech
Financial Services
Finance
Franchise
Digital Media
Non Profit
Android
Internet
Proptech
Mobile Advertising
Enterprise
Impact
Community
Sustainability
Media (Entertainment)
Hardware
Biotech
Transportation
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Hong Kong
Zimbabwe
Tunisia
Sweden
Oceania
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Lesotho
Kyrgyzstan
Isle of Man
Norway
Liberia
Malawi
Mexico
Nepal
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Colombia
Cameroon
Guernsey
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Panama
Nicaragua
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Jamaica
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Ghana
Denmark
Georgia
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Portugal
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bangladesh
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Jennifer Jin, Partner at Advantech Capital

Jennifer Jin

Partner @ Advantech Capital

Central, Hong Kong

Jennifer Jin is a Series B investor at Advantech Capital in Central focused on Medical and Health Care. Jennifer Jin is the Partner of Advantech Capital.

Total investments:
1
Last investment:
Lead investor:
100%

Last updated:

Industries Jennifer Jin invests in

MedicalHealth CareTherapeuticsBiotechnologyClinical Trials

Stages Jennifer Jin invests in

Series B

Countries Jennifer Jin invests in

China

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Medical 1 (100%)
  • Health Care 1 (100%)
  • Therapeutics 1 (100%)
  • Biotechnology 1 (100%)
  • Clinical Trials 1 (100%)

Investments

CompanyDescriptionRoundLinks
Connect Biopharmaceuticals Connect Biopharmaceuticals
Connect Biopharmaceuticals is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. They identify and advance our drug candidates through in-house discovery and in-licensing while leveraging qualified CROs for further development. The company successfully completed a phase Iclinical trial study on our leading program CBP-307, a novel and selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis.Connect Biopharmaceuticals currently conducting two phases 2 clinical studies in patients with ulcerative colitis and Crohn's disease with their lead drug candidate CBP-307. It also concluding a phase 1 study of our second drug candidate CBP-201 in healthy subjects, with a phase 1b study in atopic dermatitis patients expected to commence in Q1, 2019. Connect Biopharmaceuticals was founded in 2012 and is headquartered in Taichang, China. $55M / Series B / Jan 03, 2019

Co-Investors

Advantech Capital

About Advantech Capital

VC Fund · Central, Hong Kong

Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.

Advantech Capital Contacts

NameEmailPhoneSocials
Hebert Kee Chan Pang
Hebert Kee Chan Pang Director
Jennifer Jin
Jennifer Jin Partner
Benjamin Qiu
Benjamin Qiu Partner
Jianming Yu
Jianming Yu Founder, Managing Partner
Jianming Yu
Jianming Yu Founder, Managing Partner

Sign up to unlock verified contacts

Unlock Contacts

See all contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Energy
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Sports
Education
Automotive
Wellness
Biotechnology
eSports
Legal
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Recruiting
Infrastructure
Web3
Medical
Beauty
Fashion
Theatre
Climate
Life Science
LGBT
Food and Beverage
Cannabis
Publishing
Celebrity
Mobile Apps
Music
Wine and Spirits
Art
Real Estate
Sporting Goods
Manufacturing
Social Media
FinTech
Financial Services
Finance
Franchise
Digital Media
Non Profit
Android
Internet
Proptech
Mobile Advertising
Enterprise
Impact
Community
Sustainability
Media (Entertainment)
Hardware
Biotech
Transportation
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Hong Kong
Zimbabwe
Tunisia
Sweden
Oceania
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Lesotho
Kyrgyzstan
Isle of Man
Norway
Liberia
Malawi
Mexico
Nepal
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Colombia
Cameroon
Guernsey
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Panama
Nicaragua
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Jamaica
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Ghana
Denmark
Georgia
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Portugal
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bangladesh
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Jennifer Jin invest in?

Jennifer Jin invests primarily in Medical, Health Care and Therapeutics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Jennifer Jin?

Public channels for Jennifer Jin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Jennifer Jin last invest?

The most recent investment recorded for Jennifer Jin closed in Jan 2019. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Jennifer Jin Jennifer Jin Find email